Xcout IntelSign inSubscribe

BRONCUS-B competitors & alternatives

02216Medical DevicesUnited States

The 12 closest competitors and alternatives to BRONCUS-B among medical devices companies — ranked by similarity to what BRONCUS-B actually does, not by market-cap band.

$51MMarket cap
191Employees
12Competitors listed

Subscribe to see BRONCUS-B’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About BRONCUS-B

Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.

BRONCUS-B at a glance

BRONCUS-B is a medical devices company headquartered in United States. It is publicly listed (02216) with a market capitalisation of $51M.

Top 12 BRONCUS-B competitors

Ranked by semantic similarity — how close each company is to BRONCUS-B by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Pulmonx CorporationLUNG · Medical DevicesRedwood City, United States
69% matchPublic

Similar medical devices company

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Market cap$76.2M
Employees296
Pulmonx Corporation competitors & alternatives →
EDGE MEDICAL-B02675 · Medical DevicesChina
67% matchPublic

Similar medical devices company

Shenzhen Edge Medical Co., Ltd. engages in designing, developing, manufacturing, and sale of surgical robots in Europe, and China. The company focus on surgical robots and instruments for minimally invasive surgery or MIS, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots. Its products include Edge Multi-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS using robotic, imaging, and digital technologies; Edge Single-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS through a single small incision or natural orifice; Edge Cloud Telesurgery System; and Edge Bronchoscope Robot. The company also develops and manufactures instruments for Edge Multi-Port Endoscopic Surgical Robot and Single-Port Endoscopic Surgical Robot includes bipolar grasping forceps, bipolar separation forceps, needle holder forceps, monopolar scissors, monopolar electric hooks and other surgical tools. In addition, the company develops an non-invasive surgery by developing natural orifice surgical robots. It serves hospitals. The company sells its products through distributors. The company was formerly known as Shenzhen Jingfeng Medical Technology Co., Ltd. The company was incorporated in 2017 and is based in Shenzhen, China.

Market cap$1.6B
Employees602
EDGE MEDICAL-B competitors & alternatives →
Butterfly Network, Inc.BFLY · HealthcareBurlington, United States
65% matchPublic

Healthcare

Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks. Additionally, Butterfly Blueprint is offered as a comprehensive, system-wide ultrasound platform that seamlessly integrates its proprietary Compass software into a healthcare provider's clinical and administrative infrastructure. These ultrasound systems, encompassing probes, related accessories, and software subscriptions, are supplied to healthcare systems, individual physicians, and other medical professionals through a multi-channel distribution strategy that includes a direct sales force, a network of distributors, and an e-commerce platform. Beyond its hardware, Butterfly Network provides a suite of cloud-based software solutions for healthcare organizations. These offerings feature teleguidance services, interactive in-app educational modules, and structured training programs delivered via its Butterfly Academy software, all complemented by dedicated clinical support and services. Established in 2011, Butterfly Network, Inc. has its corporate headquarters situated in Guilford, Connecticut.

Market cap$2.2B
Employees220
Butterfly Network, Inc. competitors & alternatives →
ZYLOXTB02190 · Medical DevicesChina
65% matchPublic

Similar medical devices company

Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.

Market cap$764.2M
Employees925
ZYLOXTB competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of BRONCUS-B and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for BRONCUS-Band every competitor above — in one live dashboard.

Subscribe to Xcout Intel →